



1636

PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/900,699
	Filing Date	July 6, 2001
	First Named Inventor	Thomas J. Brennan
	Art Unit	1636
	Examiner Name	Celine X. Qian
Total Number of Pages in This Submission	Attorney Docket Number	R-173

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

RECEIVED

FEB 13 2003

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Kelly L. Quast, Reg. No. 52,141
Signature	<i>Kelly L. Quast</i>
Date	February 5, 2003

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: February 5, 2003	
Typed or printed	Don Mixon
Signature	<i>Don Mixon</i>
Date	February 5, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#15/a
Yuta
2/22/03

Applicant: Thomas J. BRENNAN

Serial No.: 09/900,699

Filed: July 6, 2001

Title: Transgenic Mice Containing DEZ Orphan
Receptor Gene Disruptions

Group Art Unit: 1636

Examiner: Qian, Celine X.

Customer No. 26619

Docket/Order No. R-173

Date: February 5, 2003

AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed November 5, 2002 in connection with the above-identified application, Applicant requests entry and consideration of the following amendments and remarks.

RECEIVED

FEB 13 2003

TECH CENTER 1600/2900

THE AMENDMENTS

In the Claims:

Please cancel claims 1-10 and 17-19.

Please add claims 21-27 below.

21. (New) A transgenic mouse comprising a disruption in an endogenous DEZ receptor gene, wherein where the disruption is homozygous, the transgenic mouse lacks production of functional DEZ receptor protein and exhibits decreased agility or coordination, relative to a wild-type mouse.
22. (New) The transgenic mouse of claim 21, wherein the decreased agility or coordination is characterized by decreased performance on an accelerating rotarod.
23. (New) A cell or tissue isolated from the transgenic mouse of claim 21.